Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.

Phase 2

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries

H. Lundbeck A/S

Rasagiline